Serum irisin levels are associated with adverse cardiovascular outcomes in patients with acute myocardial infarction

Hsieh, I‐Chang; Ho, Ming-Yun; Wen, Ming‐Shien; Chen, Chun‐Chi; Lin, Chia‐Pin; Yeh, Jiun‐Ting; Tsai, Ming-Lung; Yang, Chia‐Hung; Wu, Victor Chien‐Chia; Hung, Kuo‐Chun; Wang, Chun‐Chieh; Wang, Chao-Yung

doi:10.1016/j.ijcard.2017.11.072

Cited by 41 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In consistence with the findings of the present study, Anastasilakis et al (22) reported that serum irisin level was significantly lower in males than females. According to the analysis of studies in the literature investigating the association between various types of heart diseases and serum irisin levels in humans and animals, in general, serum irisin levels significantly decreased in cardiovascular diseases (CVD), consistent with the findings of the present study (23)(24)(25)(26)(27)(28)(29). In addition, a study reported that serum irisin levels were significantly lower in patients with major cardiovascular problems, stable coronary artery disease (CAD), or (MI) ( 23).…”

Section: Discussionsupporting

confidence: 88%

Common single nucleotide polymorphisms in the FNDC5 gene and serum irisin levels in acute myocardial infarction

Etem

Diş

Tektemur

et al. 2021

The Anatolian Journal of Cardiology

View full text Add to dashboard Cite

Objective: Acute myocardial infarction (AMI) is the most common type of coronary artery disease. The irisin hormone encoded by the fibronectin type III domain-containing protein-5 (FNDC5) gene is synthesized in muscle, heart, and fat tissues. The present study aims to investigate serum irisin concentrations and FNDC5 genetic variants in patients with AMI through comparison with controls. Methods: This study included 225 patients with AMI and 225 healthy subjects. Blood samples were obtained from patients during the first 1-24 hours after AMI. Serum irisin concentration was measured with enzyme-linked immunosorbent assay (ELISA). The variants of rs16835198, rs3480, and rs726344 in the FNDC5 gene were genotyped with real time polymerase chain reaction (RT-PCR). Results: Compared with control serum irisin concentrations were significantly lower in patients with AMI. Serum irisin concentrations of patients with AMI showed a significant and gradual decrease from 6 hours up to 24 hours (p<0.05). There were no significant differences between the patient and control groups based on genotype and allele frequencies of rs16835198, rs3480, and rs726344 in the FNDC5 gene (p>0.05). However, the frequency of the TT genotype in male patients with AMI (6.4%) was significantly lower compared with control male subjects (16.2%). In addition, the GGT haplotype was identified as the protective haplotype against the risk of AMI (p<0.001; odds ratio=0.107). Conclusions:The findings of the study suggest that serum irisin concentration could serve as a novel biological marker for the early diagnosis of AMI.

show abstract

Section: Discussionsupporting

confidence: 88%

Common single nucleotide polymorphisms in the FNDC5 gene and serum irisin levels in acute myocardial infarction

Etem

Diş

Tektemur

et al. 2021

The Anatolian Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…Further monitoring of myocardial infarction rats showed that the serum irisin level was highly positively correlated with QRS duration, amplitude and TAS, while highly negatively correlated with ST-elevation, QTc, CK-MB, troponin and MDA ( 82 ). Similar changing pattern can be observed in human that the concentration of irisin fluctuates during ACS, but the point of time was delayed ( 83 , 84 ). Similarly, the serum irisin measured 6 hours after PCI also decreased from baseline ( 76 ).…”

Section: Irisin In Chdsupporting

confidence: 80%

“…In terms of surgery, the level of irisin at 6 months after PCI was higher than the baseline ( 53 ). The relatively high level of irisin was positively correlated with the incidence of postoperative major adverse cardiovascular events (MACE), especially angina, the risk of which increased by almost 4 times (hazard ratio=3.96) ( 83 ). On the contrary, a meta-analysis involving 867 patients and 700 controls showed that patients with cardiovascular disease or atherosclerosis had significantly lower levels of irisin ( 90 ).…”

Section: Irisin In Chdmentioning

confidence: 99%

The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease

Ou-Yang

Guo

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

Irisin, a PGC1α-dependent myokine, was once believed to have beneficial effects induced by exercise. Since its first discovery of adipose browning in 2012, multiple studies have been trying to explore the metabolic functions of irisin, such as glucose and lipid metabolism. However, recently many studies with irisin concentration measuring were doubt for methodological problems, which may account for the continuous inconsistencies. New tools like recombinant irisin and gene-knockout mice are required to reconfirm the questioned functions of irisin. In this paper, we make a critical introduction to the latest researches concerning the relationship between irisin and coronary heart disease, which includes atherosclerosis, stable angina pectoris and acute coronary syndromes. These studies provided various controversial evidence of short and long-term monitoring and therapeutic effect from molecular cellular mechanisms, in vivo experiments and epidemiological investigation. But with ambiguities, irisin still has a long way to go to identify its functions in the clinical management.

show abstract

“…The level of this adipomyokineis elevated in post-STEMI patients with increased risk for adverse cardiovascular events. That is why the authors concluded that therapies targeting irisin may represent a new direction in future treatment [16]. A study by Silvestrini A et al found higher level of irisin in HFpEF than in HFrEF patients (7.72 ± 0.76 vs. 2.77 ± 0.77 ng/mL, respectively).…”

Section: Discussionmentioning

confidence: 99%

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Sobieszek

Powrózek

Mazurek

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Cachexia is an unfavorable metabolic syndrome causing involuntary weight loss followed by muscle wasting, which can lead to the exacerbation of chronic heart failure (CHF), and considerably increases mortality rate among CHF patients. Unfortunately, until now it has not been possible to determine factors that could improve clinical options for cachexia management or enable the identification of patients at risk of its development. We assessed how cachexia conditions in CHF reflect cardiac and laboratory parameters in comparison with non-cachectic patients. Methods: 66 women were enrolled to the study group and underwent meticulous screening, according to recent clinical guidelines, in order to enable CHF and cachexia detection. Body composition was evaluated by bioelectrical impedance analysis (BIA) and laboratory tests were supplemented by analysis of plasma circulating irisin. Results: A negative correlation between irisin concentration and both CRP and TNF-α was recorded (R = −0.362 and R = −0.243; p < 0.05). Irisin concentration positively correlated with EF% (R = 0.253; p = 0.046) and negatively with LVESd, LVEDd and NT-proBNP (R = −0.326, −0.272, and −0.320; p < 0.05). Both low levels of circulating irisin and Capacitance of membrane (Cm) were selected as unfavorable factors affecting cachexia in CHF patients (OR = 1.39 and 34.49; p < 0.05). Combination of Cm, irisin, CRP and albumin demonstrated sensitivity of 93.3% and specificity of 85.3% (AUC = 0.949) for distinguishing between cachectic and non-cachectic CHF patients. Conclusions: Selected parameters reliably reflect cachectic conditions in CHF, and the proposed approach for cachexia based on the combined analysis of at least a few non-invasive markers could offer new opportunities for improving clinical outcomes in CHF patients.

show abstract

Serum irisin levels are associated with adverse cardiovascular outcomes in patients with acute myocardial infarction

Cited by 41 publications

References 36 publications

Common single nucleotide polymorphisms in the FNDC5 gene and serum irisin levels in acute myocardial infarction

Common single nucleotide polymorphisms in the FNDC5 gene and serum irisin levels in acute myocardial infarction

The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Contact Info

Product

Resources

About